Microsatellite Alterations of Plasma DNA in Non-Small Cell Lung Cancer

被引:0
作者
Kim, Kyu-Sik [1 ,2 ]
Kim, Eun-Jung [2 ]
Kim, Soo-Ock [2 ]
Oh, In-Jae [2 ]
Park, Chang-Min [2 ]
Jeong, Ju-Yeon [1 ,2 ]
Kim, Yu-Il [2 ]
Lim, Sung-Chul [2 ]
Park, Jong-Tae [3 ]
Kim, Young-Chul [1 ,2 ]
机构
[1] Chonnam Natl Univ, Hwasun Hosp, Lung & Esophageal Canc Clin, Hwasun, South Korea
[2] Chonnam Natl Univ, Sch Med, Dept Pulmonol & Crit Care Med, Hwasun, South Korea
[3] Chonnam Natl Univ, Sch Med, Dept Forens Med, Hwasun, South Korea
关键词
Non-Small Cell Lung cancer; Microsatellite Alteration; Plasma DNA;
D O I
10.4046/trd.2005.58.4.352
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Microsatellites are short tandem repeated nucleotide sequences that are present throughout the human genome. Variations in the repeat number or a loss of heterozygosity around the microsatellites have been termed a microsatellite alteration (MA). A MA reflects the genetic instability caused by an impairment in the DNA mismatch repair system and is suggested to be a novel tumorigenic mechanism. A number of studies have reported that MA in the DNA extracted from the plasma occurs at varying frequencies among patients with a non-small cell lung carcinoma (NSCLC). The genomic DNA from 9 subjects with a non-small cell lung cancer (squamous cell cancer 6, adenocarcinoma 2, non-small cell lung cancer1) and 9 age matched non-cancer control subjects (AMC: tuberculosis 3, other inflammatory lung disease 6) and 12 normal control subjects (NC) were extracted from the peripheral blood leukocytes and plasma. Three microsatellite loci were amplified with the primers targeting the Gene Bank sequence D21S1245, D3S1300, and D3S1234. MA in the form of an allelic loss or a band shift was examined with 6% polyacrylamide gel electrophoresis and silver staining. None (0/12) of the NC subjects less than 40 years of age showed a MA in any of the three markers, while 88.9%(8/9) of the AMC above 40 showed a MA in at least one of the three markers (p< 0.05). Sixty percent(6/10) of the control subjects with a smoking history showed a MA in one of the three markers, while 9.1%(1/11) of the control subjects without smoking history showed a MA (p< 0.05). However, not only did 66.7%(6/9) of lung cancer patients show a MA in at least one of the three markers but so did 88.9%(8/21) of the AMC patients (p> 0.05). In conclusion, a MA in the D21S1245, D3S1300, and D3S1234 loci using DNA extracted from the plasma was detected in 66.7% of lung cancer while no MA was found in the young non-smoking control subjects. However, many of the non-cancer control subjects (aged smokers) also showed a MA, which compromised the specificity of the MA analysis as a screening test. Therefore, a further study with a larger sample size will be needed.
引用
收藏
页码:352 / 358
页数:7
相关论文
共 50 条
  • [31] Microsatellite instability and loss of heterozygosity at chromosomes 9 and 17 in non-small cell lung cancer
    Froudarakis, ME
    Sourvinos, G
    Fournel, P
    Bouros, D
    Vergnon, JM
    Spandidos, DA
    Siafakas, NM
    CHEST, 1998, 113 (04) : 1091 - 1094
  • [32] Allelotype of non-small cell lung cancer
    Neville, EM
    Stewart, MP
    Swift, A
    Liloglou, T
    Ross, H
    Gosney, JR
    Donnelly, RJ
    Field, JK
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1996, 9 (03) : 533 - 539
  • [33] Docetaxel and non-small cell lung cancer
    Le Guen, Y
    Le Cesne, A
    BULLETIN DU CANCER, 2004, 91 (03) : 263 - 270
  • [34] Concomitant genetic alterations are associated with plasma D-dimer level in patients with non-small cell lung cancer
    Chang, Fangqun
    Zhang, Hao
    Chen, Chen
    Ke, Zhangyan
    Zhao, Meiling
    Fan, Xiaoyun
    Zhang, Yanbei
    FUTURE ONCOLOGY, 2022, 18 (06) : 679 - 690
  • [35] Characterization of genetic alterations in brain metastases from non-small cell lung cancer
    Liao, Li
    Ji, Xiaoyu
    Ge, Mengxi
    Zhan, Qiong
    Huang, Ruofan
    Liang, Xiaohua
    Zhou, Xinli
    FEBS OPEN BIO, 2018, 8 (09): : 1544 - 1552
  • [36] Alterations in erythrocyte membrane protein composition in advanced non-small cell lung cancer
    Hernandez-Hernandez, Angel
    Rodriguez, Marina C.
    Lopez-Revuelta, Abel
    Sanchez-Gallego, Jose I.
    Shnyrov, Valery
    Llanillo, Marcial
    Sanchez-Yague, Jesus
    BLOOD CELLS MOLECULES AND DISEASES, 2006, 36 (03) : 355 - 363
  • [37] Necitumumab for non-small cell lung cancer
    Greillier, Laurent
    Tomasini, Pascale
    Bariesi, Fabrice
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 (08) : 1231 - 1239
  • [38] Staging of non-small cell lung cancer
    Heigener, D. F.
    Deppermann, K. -M.
    Sebastian, M.
    Reck, M.
    ONKOLOGE, 2011, 17 (08): : 679 - 683
  • [39] Non-small cell lung cancer in China
    Chen, Peixin
    Liu, Yunhuan
    Wen, Yaokai
    Zhou, Caicun
    CANCER COMMUNICATIONS, 2022, 42 (10) : 937 - 970
  • [40] Anthacyclines in non-small cell lung cancer
    Pronzato, P
    Vigani, A
    Tognoni, A
    Vaira, F
    Canessa, P
    LUNG CANCER, 2001, 34 : S57 - S59